Progress of immunotherapy in chronic lymphocytic leukemia
10.3760/cma.j.cn115356-20210325-00013
- VernacularTitle:慢性淋巴细胞白血病免疫治疗研究进展
- Author:
Jing LUO
1
;
Jianqing MI
Author Information
1. 上海交通大学医学院附属瑞金医院血液科，上海 200025
- Keywords:
Leukemia, lymphocytic, chronic, B-cell;
Immunotherapy;
Receptors, antigen, T-cell
- From:
Journal of Leukemia & Lymphoma
2021;30(6):380-384
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lymphocytic leukemia (CLL) is a heterogeneous, mature B-cell clonal malignancy that mainly affects the senior. The immunotherapies such as chimeric antigen receptor T cell therapy, bi/tri-specific cell binding agent, immune check point therapy, etc., pave several new avenues for CLL treatment, especially the combined applications of new and existing therapies have shown improved efficacy and safety. This article attempts to review the immunotherapies and their combinatorial applications in CLL.
